174 related articles for article (PubMed ID: 32359920)
1. Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities.
Boere T; Huis In 't Veld EA; Deroose JP; van Ginhoven TM; Wouters MWJM; Grünhagen DJ; Verhoef C; van Houdt WJ
Eur J Surg Oncol; 2020 Jul; 46(7):1315-1319. PubMed ID: 32359920
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ
Eur J Cancer; 2017 Nov; 85():114-121. PubMed ID: 28918185
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
van Ginkel RJ; Thijssens KM; Pras E; van der Graaf WT; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2007 Apr; 14(4):1499-506. PubMed ID: 17253101
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
7. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
Deroose JP; van Geel AN; Burger JW; Eggermont AM; Verhoef C
J Surg Oncol; 2012 May; 105(6):563-9. PubMed ID: 22020863
[TBL] [Abstract][Full Text] [Related]
9. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
[TBL] [Abstract][Full Text] [Related]
10. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.
Smith HG; Wilkinson MJ; Smith MJF; Strauss DC; Hayes AJ
Eur J Cancer; 2018 Sep; 100():46-54. PubMed ID: 29940423
[TBL] [Abstract][Full Text] [Related]
11. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study.
Reijers SJM; Davies E; Grünhagen DJ; Fiore M; Honore C; Rastrelli M; Vassos N; Podleska LE; Niethard M; Jakob J; Perhavec A; Duarte C; González F; Deroose JP; Stas M; Boecxstaens V; Schrage Y; Snow H; Algarra SM; Said HM; Garcia-Ortega DY; Martin K; Mattsson J; Djafarrian R; Di Lorenzo G; Colombo C; Gronchi A; Matter M; Verhoef C; Olofsson Bagge R; Hohenberger P; Hayes AJ; van Houdt WJ
Eur J Cancer; 2023 Sep; 190():112949. PubMed ID: 37453241
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review.
Bhangu A; Broom L; Nepogodiev D; Gourevitch D; Desai A
Eur J Surg Oncol; 2013 Apr; 39(4):311-9. PubMed ID: 23351681
[TBL] [Abstract][Full Text] [Related]
13. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
[TBL] [Abstract][Full Text] [Related]
14. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
[TBL] [Abstract][Full Text] [Related]
15. Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.
Andreou D; Werner M; Pink D; Traub F; Schuler MK; Gosheger G; Jobke B; Reichardt P; Tunn PU
Int J Hyperthermia; 2016; 32(2):159-64. PubMed ID: 26670477
[TBL] [Abstract][Full Text] [Related]
16. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity.
Hoven-Gondrie ML; Thijssens KM; Van den Dungen JJ; Loonstra J; van Ginkel RJ; Hoekstra HJ
Ann Surg Oncol; 2007 Jul; 14(7):2105-12. PubMed ID: 17457649
[TBL] [Abstract][Full Text] [Related]
17. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome.
Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
J Surg Oncol; 2011 Jun; 103(7):648-55. PubMed ID: 21337343
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma.
Lev-Chelouche D; Abu-Abeid S; Merimsky O; Isakov J; Kollander Y; Meller I; Klausner JM; Gutman M
Arch Surg; 1999 Feb; 134(2):177-80. PubMed ID: 10025459
[TBL] [Abstract][Full Text] [Related]
19. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution.
Pennacchioli E; Deraco M; Mariani L; Fiore M; Mussi C; Collini P; Olmi P; Casali PG; Santinami M; Gronchi A
Ann Surg Oncol; 2007 Feb; 14(2):553-9. PubMed ID: 17122991
[TBL] [Abstract][Full Text] [Related]
20. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
